Nanotechnology Now

Heifer International

Wikipedia Affiliate Button


Home > Press > Nanotechnology and Life Sciences: Science and Business Perspectives

Dr Mostafa Analoui, PHD, Senior Director at Pfizer Global Research and Development is confirmed to speak on critical needs in clinical diagnostics and key challenges in drug discovery and development at Biopharmaceutical Nanotechnology in London, UK on 31st March - 1st April 2008.

Nanotechnology and Life Sciences: Science and Business Perspectives

Connecticut, USA and London, UK | Posted on January 17th, 2008

Research and Development in Life Sciences are greatly impacted by recent advances in conventional and emerging technologies, especially in understanding of disease, drug discovery, and novel diagnostics. These technological contributions have led to innovation and introduction of a number of therapeutic solutions with notable improvement in public health. Nanobiotechnology, a basket of wide ranging technologies, is being positioned as one of critical class of technologies, with broad reaching impacts in Life Science R&D, including drug discovery, formulation, delivery, clinical assessment and monitoring.

Nanobiotechnology's impact within drug discovery and development is manifesting itself in two ways, with different time horizons. The immediate and short term impact is being materialized through innovative formulation and delivery of compounds in different stages of development, including the ones already in the market. In the longer term horizon, there is a promise of new class of drugs designed around nanobiotechnology approach from ground up. There are early indicators of such potential success stories worth allocating resources and attention.

Dr Mostafa Analoui's presentation at the Biopharmaceutical Nanotechnology conference in London, UK will discuss some of the areas that nanobiotechnology could play through enhancement in current paradigm, as well as new directions in drug development, using examples of current utility of nanotechnology, as well as ongoing research areas. Dr Analoui will also provide delegates with a snapshot of global business and investment environment around nanobiotechnology, including current and projected level of private and government investments, trends in IP ownership, as well as fundamental questions around assessment of investment strategies and risks.

As well as being a Senior Director at Pfizer Global Research and Development in Connecticut Dr Analoui is also adjunct Professor of Radiology and Oral Pathology, Medicine at Indiana University Schools of Medicine and Dentistry. Dr Analoui is actively involved in management and scientific/business development of novel biotechnologies and methodologies, global strategies and education. Dr Analoui was previously the Director of Oral and Maxillofacial Imaging Research at Indiana University, and Associate professor of Biomedical Engineering and Electrical & Comp Engineering at Purdue University. He was also President and CEO of Therametric Technology Inc.

In addition to industry leadership in biomedical filed, he lectures nationally and internationally. He has also served on various scientific and business advisory committees and boards. Dr. Analoui has authored over 130 publications, including journal articles, book chapters, and technical reports.


About Biopharmaceutical Nanotechnology 2008
The use of Nanotechnology in the discovery and development of biopharmaceuticals is a major breakthrough, with the potential to revolutionise and enhance your ability to develop new and innovative products.

Biopharmaceutical Nanotechnology is the first industry-led event in Europe focussing on drug discovery, drug delivery and particular therapeutic areas. Join global experts for a practical, commercially applicable perspective on how to:

Stay competitive by applying the experience of key industry players who have used nanotechnology in the administration of drugs

Discover how nanotechnology combines drugs and devices to increase your product efficiency

Learn the best ways to implement drug discovery techniques into your business processes

Discuss how to employ latest therapeutic developments into your product pipeline

For further information, visit

For more information, please click here

Copyright © Biopharmaceutical Nanotechnology 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Discovery of nanotubes offers new clues about cell-to-cell communication July 2nd, 2015

Nanospiked bacteria are the brightest hard X-ray emitters July 2nd, 2015

Engineering the world’s smallest nanocrystal July 2nd, 2015

Producing spin-entangled electrons July 2nd, 2015


Nanospiked bacteria are the brightest hard X-ray emitters July 2nd, 2015

Engineering the world’s smallest nanocrystal July 2nd, 2015

Producing spin-entangled electrons July 2nd, 2015

NIST Group Maps Distribution of Carbon Nanotubes in Composite Materials July 2nd, 2015


Leti Announces Launch of First European Nanomedicine Characterisation Laboratory: Project Combines Expertise of 9 Partners in 8 Countries to Foster Nanomedicine Innovation and Facilitate Regulatory Approval July 1st, 2015

How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems June 29th, 2015

Graphene breakthrough as Bosch creates magnetic sensor 100 times more sensitive than silicon equivalent June 28th, 2015

Spain nanotechnology featured at NANO KOREA 2015 June 26th, 2015

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
University Technology Transfer & Patents
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project